Clinical-stage Australian biotech company HaemaLogiX has entered into a co-development agreement with the Peter MacCallum Cancer Centre to conduct the first-in-human Phase 1 trial of its CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma. …
HaemaLogiX and Peter MacCallum Cancer Centre announce CAR-T clinical trial agreement
July 26, 2023 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News -
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News